Acne: boosting isotretinoin with an antihistamine?

By Ana Espino | Published on March 30, 2026 | 3 min read


Acne vulgaris is a common inflammatory skin disease that significantly impacts quality of life and is associated with both physical and psychological complications. Its pathophysiology involves a combination of seborrhea, inflammation, abnormal keratinization, and bacterial proliferation.  

Oral isotretinoin is the gold standard treatment for moderate to severe forms. However, its use is limited by frequent adverse effects, particularly skin dryness, pruritus, and initial inflammatory flares, which can compromise treatment adherence.   In this context, desloratadine—a second-generation antihistamine with anti-inflammatory and antipruritic properties—may improve both the tolerability and efficacy of treatment.  

This updated meta-analysis, published in 2026 in the Journal of Dermatological Treatment, aims to compare the combination of isotretinoin + desloratadine with isotretinoin monotherapy, assessing clinical efficacy, tolerability, and patient-centered outcomes.